223 related articles for article (PubMed ID: 22076177)
1. Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases.
Alonso-Ramirez R; Loisel S; Buors C; Pers JO; Montero E; Youinou P; Renaudineau Y
Arthritis; 2010; 2010():130646. PubMed ID: 22076177
[TBL] [Abstract][Full Text] [Related]
2. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome.
Alonso R; Buors C; Le Dantec C; Hillion S; Pers JO; Saraux A; Montero E; Marianowski R; Loisel S; Devauchelle V; Youinou P; Renaudineau Y
J Autoimmun; 2010 Dec; 35(4):336-41. PubMed ID: 20810246
[TBL] [Abstract][Full Text] [Related]
4. Gene Variation at Immunomodulatory and Cell Adhesion Molecules Loci Impacts Primary Sjögren's Syndrome.
Casadó-Llombart S; Gheitasi H; Ariño S; Consuegra-Fernández M; Armiger-Borràs N; Kostov B; Ramos-Casals M; Brito-Zerón P; Lozano F
Front Med (Lausanne); 2022; 9():822290. PubMed ID: 35372412
[TBL] [Abstract][Full Text] [Related]
5. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.
Bowen MA; Patel DD; Li X; Modrell B; Malacko AR; Wang WC; Marquardt H; Neubauer M; Pesando JM; Francke U
J Exp Med; 1995 Jun; 181(6):2213-20. PubMed ID: 7760007
[TBL] [Abstract][Full Text] [Related]
6. CD318 is a ligand for CD6.
Enyindah-Asonye G; Li Y; Ruth JH; Spassov DS; Hebron KE; Zijlstra A; Moasser MM; Wang B; Singer NG; Cui H; Ohara RA; Rasmussen SM; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6912-E6921. PubMed ID: 28760953
[TBL] [Abstract][Full Text] [Related]
7. The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations.
Kofler DM; Farkas A; von Bergwelt-Baildon M; Hafler DA
Curr Drug Targets; 2016; 17(6):651-65. PubMed ID: 26844569
[TBL] [Abstract][Full Text] [Related]
8. Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues.
Saifullah MK; Fox DA; Sarkar S; Abidi SM; Endres J; Piktel J; Haqqi TM; Singer NG
J Immunol; 2004 Nov; 173(10):6125-33. PubMed ID: 15528349
[TBL] [Abstract][Full Text] [Related]
9. Clinical and experimental evidence for targeting CD6 in immune-based disorders.
Consuegra-Fernández M; Lin F; Fox DA; Lozano F
Autoimmun Rev; 2018 May; 17(5):493-503. PubMed ID: 29526637
[TBL] [Abstract][Full Text] [Related]
10. Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding.
Bowen MA; Bajorath J; D'Egidio M; Whitney GS; Palmer D; Kobarg J; Starling GC; Siadak AW; Aruffo A
Eur J Immunol; 1997 Jun; 27(6):1469-78. PubMed ID: 9209500
[TBL] [Abstract][Full Text] [Related]
11. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.
Nair P; Melarkode R; Rajkumar D; Montero E
Clin Exp Immunol; 2010 Oct; 162(1):116-30. PubMed ID: 20726988
[TBL] [Abstract][Full Text] [Related]
12. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
13. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells.
Zimmerman AW; Joosten B; Torensma R; Parnes JR; van Leeuwen FN; Figdor CG
Blood; 2006 Apr; 107(8):3212-20. PubMed ID: 16352806
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the expression of a second CD6 ligand by synovial fibroblasts.
Joo YS; Singer NG; Endres JL; Sarkar S; Kinne RW; Marks RM; Fox DA
Arthritis Rheum; 2000 Feb; 43(2):329-35. PubMed ID: 10693872
[TBL] [Abstract][Full Text] [Related]
15. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes.
Singer NG; Richardson BC; Powers D; Hooper F; Lialios F; Endres J; Bott CM; Fox DA
Immunology; 1996 Aug; 88(4):537-43. PubMed ID: 8881754
[TBL] [Abstract][Full Text] [Related]
16. The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry.
Bowen MA; Bajorath J; Siadak AW; Modrell B; Malacko AR; Marquardt H; Nadler SG; Aruffo A
J Biol Chem; 1996 Jul; 271(29):17390-6. PubMed ID: 8663238
[TBL] [Abstract][Full Text] [Related]
17. Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction.
Starling GC; Whitney GS; Siadak AW; Llewellyn MB; Bowen MA; Farr AG; Aruffo AA
Eur J Immunol; 1996 Apr; 26(4):738-46. PubMed ID: 8625962
[TBL] [Abstract][Full Text] [Related]
18. The ectodomains of the lymphocyte scavenger receptors CD5 and CD6 interact with tegumental antigens from Echinococcus granulosus sensu lato and protect mice against secondary cystic echinococcosis.
Mourglia-Ettlin G; Miles S; Velasco-De-Andrés M; Armiger-Borràs N; Cucher M; Dematteis S; Lozano F
PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006891. PubMed ID: 30500820
[TBL] [Abstract][Full Text] [Related]
19. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes.
Singer NG; Mitra R; Lialios F; Richardson BC; Marks RM; Pesando JM; Fox DA; Nickoloff BJ
Immunol Lett; 1997 Jun; 58(1):9-14. PubMed ID: 9436462
[TBL] [Abstract][Full Text] [Related]
20. T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1.
da Glória VG; Martins de Araújo M; Mafalda Santos A; Leal R; de Almeida SF; Carmo AM; Moreira A
J Immunol; 2014 Jul; 193(1):391-9. PubMed ID: 24890719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
